Management of Malignant Pleural Mesothelioma

Clinics in Chest Medicine

Volumn 27, Issue 2, 2006, Pages 335-354

  West, Sophie D ^a   Lee, Y C Gary ^a,b  

^a CHURCHILL HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT; ASBESTOS; BIOLOGICAL MARKER; BLEOMYCIN; CARBOPLATIN; CISPLATIN; CORTICOSTEROID; CYANOCOBALAMIN; DOXORUBICIN; DOXYCYCLINE; FOLIC ACID; FOLIC ACID ANTAGONIST; GAMMA INTERFERON; GEMCITABINE; INTERLEUKIN 2; MESOTHELIN; METHOTREXATE; MITOMYCIN; OPIATE; PEMETREXED; RALTITREXED; RETROVIRUS VECTOR; TALC; TAMOXIFEN; TETRACYCLINE; THORIUM DIOXIDE; THYMIDINE KINASE; UNINDEXED DRUG; ZEOLITE;

ANALGESIA; BRACHYTHERAPY; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CORDOTOMY; DRUG INHIBITION; EPIDEMIC; GENE THERAPY; HEALTH CARE QUALITY; HEREDITY; HERPES SIMPLEX VIRUS; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; INCIDENCE; INDWELLING CATHETER; MULTIMODALITY CANCER THERAPY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PALLIATIVE THERAPY; PATIENT SELECTION; PERICARDIAL DISEASE; PERITONEUM MESOTHELIOMA; PHOTODYNAMIC THERAPY; PLEURA BIOPSY; PLEURA MESOTHELIOMA; PLEURECTOMY; PLEURODESIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; RASH; REVIEW; SIMIAN VIRUS 40; SKIN MANIFESTATION; SUICIDE GENE THERAPY; TESTIS TUMOR; THORACOCENTESIS; THORAX RADIOGRAPHY; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MAGNETIC RESONANCE IMAGING; MESOTHELIOMA; NEOPLASM STAGING; PHOTOCHEMOTHERAPY; PLEURAL NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; THORACOSCOPY;

EID: 33646549323     PISSN: 02725231     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccm.2006.01.004     Document Type: Review

References (163)

1. Lanphear B.P., and Buncher C.R. Latent period for malignant mesothelioma of occupational origin. J Occup Med 34 (1992) 718-721
2. Peto J., Hodgson J.T., Matthews F.E., and Jones J.R. Continuing increase in mesothelioma mortality in Britain. Lancet 345 (1995) 535-539
3. Sterman D.H., and Albelda S.M. Advances in the diagnosis, evaluation, and management of malignant pleural mesothelioma. Respirology 10 (2005) 266-283
4. Musk A.W., and de Klerk N.H. Epidemiology of malignant mesothelioma in Australia. Lung Cancer 45 Suppl 1 (2004) S21-S23
5. Leigh J., and Driscoll T. Malignant mesothelioma in Australia, 1945-2002. Int J Occup Environ Health 9 (2003) 206-217
6. Kjellstrom T., and Smartt P. Increased mesothelioma incidence in New Zealand: the asbestos-cancer epidemic has started. N Z Med J 113 (2000) 485-490
7. Gaafar R.M., and Eldin N.H. Epidemic of mesothelioma in Egypt. Lung Cancer 49 Suppl 1 (2005) S17-S20
8. Ulvestad B., Kjaerheim K., Moller B., and Andersen A. Incidence trends of mesothelioma in Norway, 1965-1999. Int J Cancer 107 (2003) 94-98
9. Takahashi K., and Karjalainen A. A cross-country comparative overview of the asbestos situation in ten Asian countries. Int J Occup Environ Health 9 (2003) 244-248
10. Kazan-Allen L. Asbestos and mesothelioma: worldwide trends. Lung Cancer 49 Suppl 1 (2005) S3-S8
11. Wagner J.C., Sleggs C.A., and Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med 17 (1960) 260-271
12. Antman K.H. Natural history and epidemiology of malignant mesothelioma. Chest 103 4 Suppl (1993) 373S-376S
13. Holt P.F. Translocation of inhaled dust to the pleura. Environ Res 31 (1983) 212-220
14. de Klerk N.H., Musk A.W., Williams V., et al. Comparison of measures of exposure to asbestos in former crocidolite workers from Wittenoom Gorge, W. Australia. Am J Ind Med 30 (1996) 579-587
15. Pass H.I., and Pogrebniak H.W. Malignant pleural mesothelioma. Curr Probl Surg 30 (1993) 921-1012
16. Lemen R.A. Chrysotile asbestos as a cause of mesothelioma: application of the Hill causation model. Int J Occup Environ Health 10 (2004) 233-239
17. Bonn D. Asbestos-the legacy lives on. Lancet 353 (1999) 1336
18. Chapman S.J., Cookson W.O., Musk A.W., and Lee Y.C. Benign asbestos pleural diseases. Curr Opin Pulm Med 9 (2003) 266-271
19. Lee Y.C., and Lane K.B. Cytokines in pleural diseases. In: Light R.W., and Lee Y.C. (Eds). Textbook of pleural diseases (2003), Arnold, London 63-89
20. Jaurand M.C., Kaplan H., Thiollet J., et al. Phagocytosis of chrysotile fibers by pleural mesothelial cells in culture. Am J Pathol 94 (1979) 529-538
21. Jaurand M.C. Mechanisms of fiber-induced genotoxicity. Environ Health Perspect 105 Suppl 5 (1997) 1073-1084
22. Jaurand M.C., and Fleury-Feith J. Pathogenesis of malignant pleural mesothelioma. Respirology 10 (2005) 2-8
23. Lee Y.C., De Klerk N.H., Henderson D.W., and Musk A.W. Malignant mesothelioma. In: Hendrick D.J., Burge P.S., Beckett W.S., and Chung A. (Eds). Occupational disorders of the lung: recognition, management and prevention (2002), Saunders, London 359-379
24. Testa J.R., and Jhanwar S.C. Genetics of malignant mesothelioma. In: Light R.W., and Lee Y.C. (Eds). Textbook of pleural diseases (2003), Arnold, London 120-130
25. Roushdy-Hammady I., Siegel J., Emri S., et al. Genetic-susceptibility factor and malignant mesothelioma in the Cappadocian region of Turkey. Lancet 357 (2001) 444-445
26. Ramos-Nino M.E., Scapoli L., Martinelli M., et al. Microarray analysis and RNA silencing link fra-1 to cd44 and c-met expression in mesothelioma. Cancer Res 63 (2003) 3539-3545
27. Gordon G.J., Jensen R.V., Hsiao L.L., et al. Translation of microarray data into clinically relevant cancer diagnostic tests using gene expression ratios in lung cancer and mesothelioma. Cancer Res 62 (2002) 4963-4967
28. Gordon G.J., Jensen R.V., Hsiao L.L., et al. Using gene expression ratios to predict outcome among patients with mesothelioma. J Natl Cancer Inst 95 (2003) 598-605
29. Singhal S., Wiewrodt R., Malden L.D., et al. Gene expression profiling of malignant mesothelioma. Clin Cancer Res 9 (2003) 3080-3097
30. Gordon G.J., Rockwell G.N., Jensen R.V., et al. Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling. Am J Pathol 166 (2005) 1827-1840
31. Hegmans J.P., Bard M.P., Hemmes A., et al. Proteomic analysis of exosomes secreted by human mesothelioma cells. Am J Pathol 164 (2004) 1807-1815
32. Lopez-Rios F., Illei P.B., Rusch V., and Ladanyi M. Evidence against a role for SV40 infection in human mesotheliomas and high risk of false-positive PCR results owing to presence of SV40 sequences in common laboratory plasmids. Lancet 364 (2004) 1157-1166
33. Manfredi J.J., Dong J., Liu W.J., et al. Evidence against a role for SV40 in human mesothelioma. Cancer Res 65 (2005) 2602-2609
34. Fleury-Feith J., Pilatte Y., and Jaurand M.C. Cells in the pleural cavity. In: Light R.W., and Lee Y.C. (Eds). Textbook of pleural diseases (2003), Arnold, London 17-34
35. Whitaker D., Henderson D.W., and Shilkin K.B. The concept of mesothelioma in situ: implications for diagnosis and histogenesis. Semin Diagn Pathol 9 (1992) 151-161
36. Henderson D.W., Shilkin K.B., and Whitaker D. Reactive mesothelial hyperplasia vs mesothelioma, including mesothelioma in situ: a brief review. Am J Clin Pathol 110 (1998) 397-404
37. Cury P.M., Butcher D.N., Corrin B., and Nicholson A.G. The use of histological and immunohistochemical markers to distinguish pleural malignant mesothelioma and in situ mesothelioma from reactive mesothelial hyperplasia and reactive pleural fibrosis. J Pathol 189 (1999) 251-257
38. Corson J.M. Pathology of diffuse malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg 9 (1997) 347-355
39. Sugarbaker D.J., Garcia J.P., Richards W.G., et al. Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma: results in 120 consecutive patients. Ann Surg 224 (1996) 288-294
40. Hulks G., Thomas J.S., and Waclawski E. Malignant pleural mesothelioma in western Glasgow 1980-6. Thorax 44 (1989) 496-500
41. King J.A., Tucker J.A., and Wong S.W. Mesothelioma: a study of 22 gases. South Med J 90 (1997) 199-205
42. Baldini E.H., Recht A., Strauss G.M., et al. Patterns of failure after trimodality therapy for malignant pleural mesothelioma. Ann Thorac Surg 63 (1997) 334-338
43. Wang N.S. Pleural mesothelioma: an approach to diagnostic problems. Respirology 1 (1996) 259-271
44. Antman K., Shemin R., Ryan L., et al. Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women's Hospital experience over two decades, 1965-1985. J Clin Oncol 6 (1988) 147-153
45. Corson J.M. Pathology of mesothelioma. Thorac Surg Clin 14 (2004) 447-460
46. Chahinian A.P., Pajak T.F., Holland J.F., et al. Diffuse malignant mesothelioma: prospective evaluation of 69 patients. Ann Intern Med 96 6 Pt 1 (1982) 746-755
47. Leigh J., Davidson P., Hendrie L., and Berry D. Malignant mesothelioma in Australia, 1945-2000. Am J Ind Med 41 (2002) 188-201
48. Lee Y.C.G., Dean A., Thompson R.I., and Robinson B.W.S. Clinical and palliative care aspects of malignant mesothelioma. In: Robinson B.W.S., and Chahinian P. (Eds). Mesothelioma (2002), Martin Dunitz, London 111-126
49. Sugarbaker P.H., Welch L.S., Mohamed F., and Glehen O. A review of peritoneal mesothelioma at the Washington Cancer Institute. Surg Oncol Clin N Am 12 (2003) 605-621
50. Vigneswaran W.T., and Stefanacci P.R. Pericardial mesothelioma. Curr Treat Options Oncol 1 (2000) 299-302
51. Eren N.T., and Akar A.R. Primary pericardial mesothelioma. Curr Treat Options Oncol 3 (2002) 369-373
52. Plas E., Riedl C.R., and Pfluger H. Malignant mesothelioma of the tunica vaginalis testis: review of the literature and assessment of prognostic parameters. Cancer 83 (1998) 2437-2446
53. Wong C.F., Fung S.L., Yew W.W., and Fu K.H. A case of malignant pleural mesothelioma with unexpectedly long survival without active treatment. Respiration 69 (2002) 166-168
54. Edwards J.G., Abrams K.R., Leverment J.N., et al. Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems. Thorax 55 (2000) 731-735
55. Herndon J.E., Green M.R., Chahinian A.P., et al. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 113 (1998) 723-731
56. Mikulski S.M., Costanzi J.J., Vogelzang N.J., et al. Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma. J Clin Oncol 20 (2002) 274-281
57. Curran D., Sahmoud T., Therasse P., et al. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol 16 (1998) 145-152
58. Pisani R.J., Colby T.V., and Williams D.E. Malignant mesothelioma of the pleura. Mayo Clin Proc 63 (1988) 1234-1244
59. Musk A.W., and Woodward S.D. Conventional treatment and its effect on survival of malignant pleural mesothelioma in Western Australia. Aust N Z J Med 12 (1982) 229-232
60. Ceresoli G.L., Locati L.D., Ferreri A.J., et al. Therapeutic outcome according to histologic subtype in 121 patients with malignant pleural mesothelioma. Lung Cancer 34 (2001) 279-287
61. Law M.R., Gregor A., Hodson M.E., et al. Malignant mesothelioma of the pleura: a study of 52 treated and 64 untreated patients. Thorax 39 (1984) 255-259
62. Boutin C., and Rey F. Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients. Part 1: diagnosis. Cancer 72 (1993) 389-393
63. Renshaw A.A., Dean B.R., Antman K.H., et al. The role of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma. Chest 111 (1997) 106-109
64. Attanoos R.L., and Gibbs A.R. Pathology of malignant mesothelioma. Histopathology 30 (1997) 403-418
65. Edge J.R., and Choudhury S.L. Malignant mesothelioma of the pleura in Barrow-in-Furness. Thorax 33 (1978) 26-30
66. Maskell N.A., Gleeson F.V., and Davies R.J. Standard pleural biopsy versus CT-guided cutting-needle biopsy for diagnosis of malignant disease in pleural effusions: a randomised controlled trial. Lancet 361 (2003) 1326-1330
67. King J.E., and Hasleton P.S. Immunohistochemistry and the diagnosis of malignant mesothelioma. Histopathology 38 (2001) 471-476
68. Wick M.R. Pleural cytology, tumor markers and immunohistochemistry. In: Light R.W., and Lee Y.C. (Eds). Textbook of pleural diseases (2003), Arnold, London 256-281
69. Robinson B.W., Creaney J., Lake R., et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 362 (2003) 1612-1616
70. Hassan R., Bera T., and Pastan I. Mesothelin: a new target for immunotherapy. Clin Cancer Res 10 12 Pt 1 (2004) 3937-3942
71. Pass H.I., Lott D., Lonardo F., et al. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 353 (2005) 1564-1573
72. Antman K.H. Current concepts: malignant mesothelioma. N Engl J Med 303 (1980) 200-202
73. Ng C.S., Munden R.F., and Libshitz H.I. Malignant pleural mesothelioma: the spectrum of manifestations on CT in 70 cases. Clin Radiol 54 (1999) 415-421
74. Yilmaz U.M., Utkaner G., Yalniz E., et al. Computed tomographic findings of environmental asbestos-related malignant pleural mesothelioma. Respirology 3 (1998) 33-38
75. Bittner R.C., and Felix R. Magnetic resonance (MR) imaging of the chest: state-of-the-art. Eur Respir J 11 (1998) 1392-1404
76. McLoud T.C. CT and MR in pleural disease. Clin Chest Med 19 (1998) 261-276
77. Byrne M.J., and Nowak A.K. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 15 (2004) 257-260
78. Nowak A.K. CT, RECIST, and malignant pleural mesothelioma. Lung Cancer 49 Suppl 1 (2005) S37-S40
79. Knuuttila A., Halme M., Kivisaari L., et al. The clinical importance of magnetic resonance imaging versus computed tomography in malignant pleural mesothelioma. Lung Cancer 22 (1998) 215-225
80. Heelan R.T., Rusch V.W., Begg C.B., et al. Staging of malignant pleural mesothelioma: comparison of CT and MR imaging. AJR Am J Roentgenol 172 (1999) 1039-1047
81. Patz Jr. E.F., Shaffer K., Piwnica-Worms D.R., et al. Malignant pleural mesothelioma: value of CT and MR imaging in predicting resectability. AJR Am J Roentgenol 159 (1992) 961-966
82. Wang Z.J., Reddy G.P., Gotway M.B., et al. Malignant pleural mesothelioma: evaluation with CT, MR imaging, and PET. Radiographics 24 (2004) 105-119
83. Benard F., Sterman D., Smith R.J., et al. Metabolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography. Chest 114 (1998) 713-722
84. Benard F., Sterman D., Smith R.J., et al. Prognostic value of FDG PET imaging in malignant pleural mesothelioma. J Nucl Med 40 (1999) 1241-1245
85. Flores R.M. Induction chemotherapy, extrapleural pneumonectomy, and radiotherapy in the treatment of malignant pleural mesothelioma: the Memorial Sloan-Kettering experience. Lung Cancer 49 Suppl 1 (2005) S71-S74
86. Steinert H.C., Santos Dellea M.M., Burger C., et al. Therapy response evaluation in malignant pleural mesothelioma with integrated PET-CT imaging. Lung Cancer 49 Suppl 1 (2005) S33-S35
87. Butchart E.G., Ashcroft T., Barnsley W.C., et al. Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura: experience with 29 patients. Thorax 31 (1976) 15-24
88. Boutin C., Rey F., Gouvernet J., et al. Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients. Part 2: prognosis and staging. Cancer 72 (1993) 394-404
89. Rusch V.W. A proposed new international TNM staging system for malignant pleural mesothelioma: from the International Mesothelioma Interest Group. Chest 108 (1995) 1122-1128
90. van Meerbeeck J.P., and Boyer M. Consensus report: pretreatment minimal staging and treatment of potentially resectable malignant pleural mesothelioma. Lung Cancer 49 Suppl 1 (2005) S123-S127
91. Robinson B.W., Musk A.W., and Lake R.A. Malignant mesothelioma. Lancet 366 (2005) 397-408
92. Jaklitsch M.T., Grondin S.C., and Sugarbaker D.J. Treatment of malignant mesothelioma. World J Surg 25 (2001) 210-217
93. Jackson M.B., Pounder D., Price C., et al. Percutaneous cervical cordotomy for the control of pain in patients with pleural mesothelioma. Thorax 54 (1999) 238-241
94. Kanpolat Y., Savas A., Ucar T., et al. CT-guided percutaneous selective cordotomy for treatment of intractable pain in patients with malignant pleural mesothelioma. Acta Neurochir (Wien) 144 (2002) 595-599
95. Price C., Pounder D., Jackson M., et al. Respiratory function after unilateral percutaneous cervical cordotomy. J Pain Symptom Manage 25 (2003) 459-463
96. Pass H.I., and Pogrebniak H.W. Malignant pleural mesothelioma. Curr Probl Surg 30 (1993) 921-1012
97. West S.D., Davies R.J., and Lee Y.C. Pleurodesis for malignant pleural effusions: current controversies and variations in practices. Curr Opin Pulm Med 10 (2004) 305-310
98. Shaw P., and Agarwal R. Pleurodesis for malignant pleural effusions. Cochrane Database Syst Rev 1 (2004) CD002916
99. Dresler C.M., Olak J., Herndon J.E., et al. Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion. Chest 127 (2005) 909-915
100. Lee Y.C., and Light R.W. Management of malignant pleural effusions. Respirology 9 (2004) 148-156
101. Putnam Jr. J.B., Light R.W., Rodriguez R.M., et al. A randomized comparison of indwelling pleural catheter and doxycycline pleurodesis in the management of malignant pleural effusions. Cancer 86 (1999) 1992-1999
102. Ball D.L., and Cruickshank D.G. The treatment of malignant mesothelioma of the pleura: review of a 5-year experience, with special reference to radiotherapy. Am J Clin Oncol 13 (1990) 4-9
103. Gordon Jr. W., Antman K.H., Greenberger J.S., et al. Radiation therapy in the management of patients with mesothelioma. Int J Radiat Oncol Biol Phys 8 (1982) 19-25
104. Alberts A.S., Falkson G., Goedhals L., et al. Malignant pleural mesothelioma: a disease unaffected by current therapeutic maneuvers. J Clin Oncol 6 (1988) 527-535
105. Munter M.W., Christian T., Anna N., et al. Inverse planned stereotactic intensity modulated radiotherapy (IMRT) in the palliative treatment of malignant mesothelioma of the pleura: the Heidelberg experience. Lung Cancer 49 Suppl 1 (2005) S83-S86
106. Boutin C., Rey F., and Viallat J.R. Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma: a randomized trial of local radiotherapy. Chest 108 (1995) 754-758
107. Boutin C., Irisson M., Rathelot P., and Petite J.M. [Parietal extension of diffuse malignant pleural mesothelioma after biopsy: prevention by local radiotherapy]. Presse Med 12 (1983) 1823
108. Bydder S., Phillips M., Joseph D.J., et al. A randomised trial of single-dose radiotherapy to prevent procedure tract metastasis by malignant mesothelioma. Br J Cancer 91 (2004) 9-10
109. Rusch V.W., Niedzwiecki D., Tao Y., et al. Intrapleural cisplatin and mitomycin for malignant mesothelioma following pleurectomy: pharmacokinetic studies. J Clin Oncol 10 (1992) 1001-1006
110. Markman M., Cleary S., Pfeifle C., et al. Cisplatin administered by the intracavitary route as treatment for malignant mesothelioma. Cancer 58 (1986) 18-21
111. van Ruth S., Baas P., Haas R.L., et al. Cytoreductive surgery combined with intraoperative hyperthermic intrathoracic chemotherapy for stage I malignant pleural mesothelioma. Ann Surg Oncol 10 (2003) 176-182
112. Byrne M.J., Davidson J.A., Musk A.W., et al. Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. J Clin Oncol 17 (1999) 25-30
113. Nowak A.K., Byrne M.J., Williamson R., et al. A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br J Cancer 87 (2002) 491-496
114. Solheim O.P., Saeter G., Finnanger A.M., et al. High-dose methotrexate in the treatment of malignant mesothelioma of the pleura: a phase II study. Br J Cancer 65 (1992) 956-960
115. Berghmans T., Paesmans M., Lalami Y., et al. Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis. Lung Cancer 38 (2002) 111-121
116. Hanauske A.R., Chen V., Paoletti P., et al. Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors. Oncologist 6 (2001) 363-373
117. Hanna N., Shepherd F.A., Fossella F.V., et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22 (2004) 1589-1597
118. Curtin N.J., and Hughes A.N. Pemetrexed disodium, a novel antifolate with multiple targets. Lancet Oncol 2 (2001) 298-306
119. Vogelzang N.J., Rusthoven J.J., Symanowski J., et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21 (2003) 2636-2644
120. Hollen P.J., Gralla R.J., Liepa A.M., et al. Adapting the Lung Cancer Symptom Scale (LCSS) to mesothelioma: using the LCSS-Meso conceptual model for validation. Cancer 101 (2004) 587-595
121. Bottomley A., Gaafa R., Manegold C., et al. Short-term treatment-related symptoms and quality of life: results from an international randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an EORTC Lung-Cancer Group and National Cancer Institute, Canada, Intergroup Study. J Clin Oncol 24 (2006) 1435-1442
122. Niyikiza C., Baker S.D., Seitz D.E., et al. Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther 1 (2002) 545-552
123. Hazarika M., White Jr. R.M., Booth B.P., et al. Pemetrexed in malignant pleural mesothelioma. Clin Cancer Res 11 (2005) 982-992
124. Adjei A.A. Pemetrexed (Alimta): a novel multitargeted antifolate agent. Exp Rev Anticancer Ther 3 (2003) 145-156
125. Adjei A.A. Pharmacology and mechanism of action of pemetrexed. Clin Lung Cancer 5 Suppl 2 (2004) S51-S55
126. Favaretto A. Overview on ongoing or planned clinical trials in Europe. Lung Cancer 49 Suppl 1 (2005) S117-S121
127. van Meerbeeck J.P., Gaafar R., Manegold C., et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 23 (2005) 6881-6889
128. Porta C., Zimatore M., Bonomi L., et al. Raltitrexed-oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients. Lung Cancer 48 (2005) 429-434
129. DaValle M.J., Faber L.P., Kittle C.F., et al. Extrapleural pneumonectomy for diffuse, malignant mesothelioma. Ann Thorac Surg 42 (1986) 612-618
130. Rusch V.W., Piantadosi S., and Holmes E.C. The role of extrapleural pneumonectomy in malignant pleural mesothelioma. A Lung Cancer Study Group trial. J Thorac Cardiovasc Surg 102 (1991) 1-9
131. van Ruth S., Baas P., and Zoetmulder F.A. Surgical treatment of malignant pleural mesothelioma: a review. Chest 123 (2003) 551-561
132. Aisner J. Current approach to malignant mesothelioma of the pleura. Chest 107 6 Suppl (1995) 332S-344S
133. Rusch V.W. Pleurectomy/decortication in the setting of multimodality treatment for diffuse malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg 9 (1997) 367-372
134. Sugarbaker D.J., Mentzer S.J., and Strauss G. Extrapleural pneumonectomy in the treatment of malignant pleural mesothelioma. Ann Thorac Surg 54 (1992) 941-946
135. Sugarbaker D.J., Mentzer S.J., DeCamp M., et al. Extrapleural pneumonectomy in the setting of a multimodality approach to malignant mesothelioma. Chest 103 4 Suppl (1993) 377S-381S
136. Kaiser L.R. New therapies in the treatment of malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg 9 (1997) 383-390
137. Sugarbaker D.J., Flores R.M., Jaklitsch M.T., et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 117 (1999) 54-63
138. Jaklitsch M.T., Grondin S.C., and Sugarbaker D.J. Treatment of malignant mesothelioma. World J Surg 25 (2001) 210-217
139. Rice T.W., Adelstein D.J., Kirby T.J., et al. Aggressive multimodality therapy for malignant pleural mesothelioma. Ann Thorac Surg 58 (1994) 24-29
140. Pass H.I., Temeck B.K., Kranda K., et al. Phase III randomized trial of surgery with or without intraoperative photodynamic therapy and postoperative immunochemotherapy for malignant pleural mesothelioma. Ann Surg Oncol 4 (1997) 628-633
141. Rusch V.W., Rosenzweig K., Venkatraman E., et al. A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 122 (2001) 788-795
142. Sugarbaker D.J., Jaklitsch M.T., Bueno R., et al. Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies. J Thorac Cardiovasc Surg 128 (2004) 138-146
143. Pilling J.E., Stewart D.J., Martin-Ucar A.E., et al. The case for routine cervical mediastinoscopy prior to radical surgery for malignant pleural mesothelioma. Eur J Cardiothorac Surg 25 (2004) 497-501
144. Sugarbaker D.J., Jaklitsch M.T., and Liptay M.J. Mesothelioma and radical multimodality therapy: who benefits?. Chest 107 6 Suppl (1995) 345S-350S
145. Stahel R.A., Weder W., Ballabeni P., et al. Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma: a multicentre phase II trial of the SAKK. Proc Am Soc Clin Oncol 23 (2004) 626a
146. Sugarbaker D.J., Strauss G.M., Lynch T.J., et al. Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma. J Clin Oncol 11 (1993) 1172-1178
147. Treasure T., Waller D., Swift S., and Peto J. Radical surgery for mesothelioma. BMJ 328 (2004) 237-238
148. Hilaris B.S., Nori D., Kwong E., et al. Pleurectomy and intraoperative brachytherapy and postoperative radiation in the treatment of malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 10 (1984) 325-331
149. Friedberg J.S., Mick R., Stevenson J., et al. A phase I study of Foscan-mediated photodynamic therapy and surgery in patients with mesothelioma. Ann Thorac Surg 75 (2003) 952-959
150. Albelda S.M., and Sterman D.H. Gene therapy in pleural diseases. In: Light R.W., and Lee Y.C. (Eds). Textbook of pleural diseases (2003), Arnold, London 526-535
151. Sterman D.H., Kaiser L.R., and Albelda S.M. Gene therapy for malignant pleural mesothelioma. Hematol Oncol Clin North Am 12 (1998) 553-568
152. Elshami A.A., Saavedra A., Zhang H., et al. Gap junctions play a role in the 'bystander effect' of the herpes simplex virus thymidine kinase/ganciclovir system in vitro. Gene Ther 3 (1996) 85-92
153. Goey S.H., Eggermont A.M., Punt C.J., et al. Intrapleural administration of interleukin 2 in pleural mesothelioma: a phase I-II study. Br J Cancer 72 (1995) 1283-1288
154. Astoul P. Pleural mesothelioma. Curr Opin Pulm Med 5 (1999) 259-268
155. Astoul P., Picat-Joossen D., Viallat J.R., et al. Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma: a Phase II study. Cancer 83 (1998) 2099-2104
156. Sterman D.H., Kaiser L.R., and Albelda S.M. Advances in the treatment of malignant pleural mesothelioma. Chest 116 (1999) 504-520
157. Boutin C., Nussbaum E., Monnet I., et al. Intrapleural treatment with recombinant gamma-interferon in early stage malignant pleural mesothelioma. Cancer 74 (1994) 2460-2467
158. Upham J.W., Musk A.W., van Hazel G., et al. Interferon alpha and doxorubicin in malignant mesothelioma: a phase II study. Aust N Z J Med 23 (1993) 683-687
159. Pass H.W., Temeck B.K., Kranda K., et al. A phase II trial investigating primary immunochemotherapy for malignant pleural mesothelioma and the feasibility of adjuvant immunochemotherapy after maximal cytoreduction. Ann Surg Oncol 2 (1995) 214-220
160. Pass H.I., Temeck B.K., Kranda K., et al. Preoperative tumor volume is associated with outcome in malignant pleural mesothelioma. J Thorac Cardiovasc Surg 115 (1998) 310-317
161. Grove C.S., and Lee Y.C. Vascular endothelial growth factor: the key mediator in pleural effusion formation. Curr Opin Pulm Med 8 (2002) 294-301
162. Catalano A., Gianni W., and Procopio A. Experimental therapy of malignant mesothelioma: new perspectives from anti-angiogenic treatments. Crit Rev Oncol Hematol 50 (2004) 101-109
163. Vogelzang N.J., Porta C., and Mutti L. New agents in the management of advanced mesothelioma. Semin Oncol 32 (2005) 336-350